|
|
|
|
| LEADER |
01369nam a2200229 a 4500 |
| 001 |
1782002 |
| 005 |
20171111234529.0 |
| 008 |
100616s2010 nyua sb 001 0 eng d |
| 020 |
|
|
|z 9781616689278 (softcover)
|z 1616689277 (softcover)
|
| 040 |
|
|
|a CaPaEBR
|z 9781617284809 (e-book)
|
| 050 |
1 |
4 |
|a RC848.F3
|b Y66 2010eb
|
| 100 |
1 |
|
|a Yoneda, Masato.
|
| 245 |
1 |
0 |
|a Insulin resistance and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH)
|c Masato Yoneda ... [et al.].
|
| 260 |
|
|
|a New York :
|b Nova Biomedical Books,
|c c2010.
|
| 300 |
|
|
|a viii, 54 p. :
|b col. ill.
|
| 490 |
1 |
|
|a Metabolic diseases--laboratory and clinical research
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a NAFLD and insulin resistance (IR) -- Pathophysiology of NASH : insulin resistance, free fatty acids, and cytokines -- Adiponectin and NASH -- TNF-[alpha] and NAFLD/NASH -- Leptin and NAFLD/NASH -- Peroxisome proliferators-activated receptors (PPARs) and NAFLD/NASH -- Iron overload and NAFLD/NASH -- Mitochondrial abnormalities and NAFLD/NASH -- Genetic influences in NAFLD/NASH -- Therapeutic strategy for NASH patients -- Natural history of NAFLD -- Conclusions.
|
| 650 |
|
0 |
|a Fatty liver.
|
| 710 |
2 |
|
|a ebrary, Inc.
|
| 856 |
4 |
0 |
|u http://site.ebrary.com/lib/ucy/Doc?id=10681073
|
| 952 |
|
|
|a CY-NiOUC
|b 5a0456e46c5ad14ac1ece64d
|c 998a
|d 945l
|e -
|t 1
|x m
|z Books
|
